## Content:
The Federal Commission for the Protection against Sanitary Risks (Cofepirs) approved the health register of enzalutamide capsule, a new molecule for the treatment of metastatic cancer of prostate.
Enzalutamine is a drug that blocks androgen receptors in cancer cells, weakening the stimulus that promotes the growth of prostate cancer.
In case you missed it: Inai offers to collaborate with Sheinbaum to improve Transparency
In Mexico, this input is already marketed in tablet form, however, the recently issued health registration is for capsule distribution. Considering that in our country, every year, 200,000 cases of prostate cancer are detected, with more than 25 thousand cases and over 7,500 deaths attributed to the disease, this authorization contributes to diversifying the therapeutic offer to treat this ailment.
It is worth noting that enzalutamide in capsules is added to the 20 medicines authorized by Cofepris during the first half of July, according to the biweekly report on therapeutic expansion.
In case you missed it: Concamin calls for stopping blockades on the Mexico-Puebla highway
Meanwhile, the approval of health supplies by Cofepris is based on rigorous evaluation processes that guarantee compliance with the highest standards of safety, quality, and efficiency.
Cofepris approves new molecule to treat prostate cancer.
— COFEPRIS (@COFEPRIS) August 8, 2024
AY/dg